TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Expectations regarding treatment options
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects with at least 20% lean-associated microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of days of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of days in the Pediatric Cardiothoracic Unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of post-operative hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prevalence of Anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of Zinc deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of Vitamin A deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dose response curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prodromal Synucleinopathy Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of metabolic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of initiation of oral anticoagulant prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of fetal loss during the 2nd and 3rd trimesters
Endpoint domain: Mortality/survival
Primary endpoint: Troponin I Elevation Above the Upper Reference Limit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heal of fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Plasma Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Weight gain prevention or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Specificity and Sensitivity of Whole Body MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole Body MRI Cellularity Index (CI) and PET/CT Standardized Uptake Value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of first permanent molars with caries lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Frequency of pimonidazole labeling in specific lesion types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of co-localization of AFB positive bacilli with pimonidazole regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Inhibition of Natural Killer Cells function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ATV exposures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smoking outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root canal volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root canal transportation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Centred ability of instruments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HEMI-Modified Melasma Area and Severity Index (mMASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absence of Grade II-IV aGVHD or Chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiometabolic phenotype score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superior mesenteric artery blood flow after a meal challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Muscle acetylcarnitine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in dyssynchrony during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in dyssynchrony during dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in dyssynchrony at rest and during peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in dyssynchrony during hospitalization for diastolic heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sexual Interest and Desire Inventory Female (SIDI-F)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Boston/Levine subjective Symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effective dose in 95% of patients (ED95) of bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety parameter
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity measured by OprF/I specific IgG antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Boston scale for bowel cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composite Rate of Death and Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Freedom From Death and Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Presence of underlying genetic cardiac mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disabilities of the Arm, Shoulder and Hand (QuickDASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of late effects after head and neck cancer treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response of IPS to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recurrence rate of neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pin-prick pain in the area of secondary hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SDBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Seroconversion rates of the booster vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Persistence (tite rates) of antibodies against poliovirus 3 years after the primary 3 dose polio vaccine immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection rates after the booster vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exclusion of periprosthetic joint infection
Endpoint domain: Adverse events/effects
Primary endpoint: HERVs-specific CD8+ T cells responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Elongation Index (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of local and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Rankin Score (mRs)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Normal bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Immunosuppression Associated Diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma and urine TMAO level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Compositional analysis of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration of Maraviroc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement assessed by WOMAC questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Perfused vascular density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pain Intensity Score at Day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity Score at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' Satisfaction for the Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Norepinephrine plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite CR (CRc) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of Symptomatic Intracranial Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Central Subfield Thickness on OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sigma parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-progression of lung metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hypoglycemia Fear Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CSF:Plasma Ratio of Rilpivirine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calculated IOL powers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL) as measured by EQ-5D-5L in patients with TS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (QoL) as measured by EQ-5D-5L in patients with KS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Minimum blood potassium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weighted mean serum cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Child absolute change from baseline BMI z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body weight correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of HMPL-011
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady State concentration of HMPL-011
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of HMPL-011
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency in adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of AZD9291 After Single Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of AZD9291 After Single Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CL/F of AZD9291 After Single Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visits to Fast Food Restaurants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Calories Purchased From Fast Food Restaurants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Times App Identifies Presence in Fast Food Restaurant (FFR)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Times App Delivers Appropriate Tailored Message
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Absence or presence of keratoconus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: improvement in HbA1c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: UA-glucuronide plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HbA1c less than 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent fall from prechallenge FEV1 during allergen challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increase from prechallenge Nasal Symptoms score during allergen challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentages of correct responses in listening tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaction times in listening tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in facial acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With Ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Neuropsychological measures of memory and attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report on memory performance in everyday activities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Assessment of psychological wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Visual Acuity (Letters) From Baseline to 1 Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay time for seeking help
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Intact Parathyroid Hormone at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants With Intact Parathyroid Hormone Within K/DOQI Target Range at Baseline and 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants With Elevated Serum-Phosphorus (s-P) Levels at Baseline and 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Elevated Serum-Calcium (s-Ca) Levels at Baseline and 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of significant clinical findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Frontostriatal Reactivity to Reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive Symptoms as Measured by the MASQ-AD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Urine F2 Alpha Isoprostane Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of genes causing Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of cardiac-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence/rate of re-intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic profile (AUCinf, AUClast, Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Infected With RSV Vaccine Virus
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in perceived social support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improvement of patients' self-esteem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decreased hemodialysis stressor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in mean PUCAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Difference Between Pre and Postoperative Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with severe cGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in glycated hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in H-reflex amplitudes of the gastrocnemius and soleus muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in isometric twitch torques of the gastrocnemius and soleus muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in three-dimensional neointimal plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Reporting Solicited Injection-Site and Solicited Systemic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients free of parasites in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: tumor objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safest dose of mifepristone
Endpoint domain: Adverse events/effects
Primary endpoint: 2019 nCoV nucleic acid detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ABT-126 levels in blood (plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical laboratory tests, vital signs and electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaspin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Omentin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hopkins Verbal Learning Test - Revised (HVLT-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Weight in kgs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in Sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in general well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in qEEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients With Undetectable HIV Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: peristomy skin complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Glycosylated Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Community Integration Scale Score at 18 Months
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Rosenberg Self-Esteem Scale Score at 18 Months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Exercise Endurance Time (EET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with severe disease receiving systemic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of spelling errors
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: resolution of diarrhea associated with C. difficile infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Initial hemostasis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Action on osteoclasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: High sensitive C - reactive protein (Hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-Form McGill Pain Questionnaire (SF-MPQ)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Pelvic Pain Impact Questionnaire (PPIQ)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Hematological recovery (Hb return to normal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean time to next infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with documented Heterotopic Ossification
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of raltegravir in cervicovaginal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop Out
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lopinavir (LPV) area under the concentration-time curve (AUC) for 0 to 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes